Clinical validation Aclarion is actively expanding CLARITY trial sites including the University of Arizona College of Medicine – Phoenix, signaling ongoing clinical validation and potential to scale adoption among spine surgeons and radiology departments.

IP and efficiency Recent patent allowances and a growing IP portfolio focused on MR Spectroscopy workflow, data accuracy, and faster scan processes suggest defensible technology advantages that can be leveraged in multi-site hospitals and imaging centers seeking differentiators.

Strategic partnerships With multiple press releases announcing new site deployments and collaboration with prominent spine programs, there are outsized opportunities to engage health systems, academic centers, and integrated delivery networks on CLARITY trial rollout and Nociscan adoption.

Economics and funding Despite sub-$1M revenue, the company has significant funding and a clear path to scale with adoption across clinics, offering a route for cost-structure discussions, pilot programs, and volume-based licensing for MRI centers.

Competitive positioning Positioning as the first evidence-supported MRS-based solution for locating pain sources in the spine provides a unique selling point against traditional imaging, enabling targeted sales conversations with neurosurgery, orthopedic spine, and radiology leadership.